Variable | Â | No. of patients | No. of events | Proportion surviving to 5 years (%) | p value |
---|---|---|---|---|---|
T stage | Â | Â | Â | Â | Â |
 | T1mic | 120 | 4 | 97.4 | 0.681 |
 | T1a | 93 | 2 | 97.8 |  |
 | T1b | 162 | 6 | 96.9 |  |
Age | Â | Â | Â | Â | Â |
 | ≤ 35 | 23 | 3 | 90.9 | 0.002 |
 | >35 | 352 | 9 | 97.7 |  |
Grade¶ |  |  |  |  |  |
 | 1 (low) | 28 | 1 | 96.3 | 0.696 |
 | 2 | 152 | 5 | 96.6 |  |
 | 3 (high) | 71 | 2 | 98.6 |  |
ERa | Â | Â | Â | Â | Â |
 | negative | 136 | 7 | 95.1 | 0.123 |
 | positive | 237 | 5 | 98.2 |  |
PRb | Â | Â | Â | Â | Â |
 | negative | 187 | 9 | 96.0 | 0.126 |
 | positive | 186 | 3 | 98.2 |  |
HR | Â | Â | Â | Â | Â |
 | ER-PR- | 122 | 7 | 94.9 | 0.069 |
 | ER+ and/or PR+ | 251 | 5 | 98.4 |  |
HER2c | Â | Â | Â | Â | Â |
 | Negative | 276 | 8 | 97.4 | 0.772 |
 | Positive | 96 | 3 | 97.9 |  |
HR/HER2 | Â | Â | Â | Â | |
 | HR+HER2- | 220 | 4 | 98.6 | 0.225 |
 | HR+HER2+ | 31 | 1 | 96.8 |  |
 | HR-HER2+ | 65 | 2 | 98.5 |  |
 | HR-HER2- | 56 | 4 | 92.6 |  |
HR/HER2 | Â | Â | Â | Â | |
 | HR+ and/or HER2+ | 316 | 7 | 98.4 | 0.018 |
 | HR-HER2- | 56 | 4 | 92.6 |  |
p53d | Â | Â | Â | Â | Â |
 | <10%; | 220 | 4 | 97.9 | 0.543 |
 | ≥10% | 143 | 6 | 97.1 |  |
Ki-67d | Â | Â | Â | Â | Â |
 | <10% | 275 | 6 | 98.4 | 0.148 |
 | ≥10% | 88 | 4 | 95.5 |  |